Pazopanib-associated secondary adrenal insufficiency in a patient with malignant solitary fibrous tumor

Basit Öğe Kaydı
dc.contributor.authorEr, Muhammed Muhiddin
dc.contributor.authorAraz, Murat
dc.contributor.authorKarabacak, Meryem
dc.contributor.authorUgrakli, Muzaffer
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-02-23T14:27:02Z
dc.date.available2024-02-23T14:27:02Z
dc.date.issued2021
dc.departmentNEÜen_US
dc.description.abstractIntroduction Pazopanib is an agent that is being successfully used in soft tissue sarcomas. Some endocrine side effects may develop during pazopanib treatment. Here, we presented a case diagnosed with secondary adrenal insufficiency while being investigated for etiology of hypoglycemia which developed after pazopanib. Case report A 69-year-old male patient was operated in June 2019 due to a lung mass 26 x 18 x 10 cm in size. Pathological diagnosis revealed a solitary fibrous tumor with malignant behavior. The patient received three lines of chemotherapy. After pazopanib treatment, a hypoglycemic attack was reported. Management and outcome: Blood cortisol and ACTH (Adrenocorticotropic hormone) levels were not increased at the time of the hypoglycemic attack, and levels of other pituitary hormones were found to be normal. Electrolyte levels were in normal range. Since the counteracting hormone did not reach a sufficient level, it was considered secondary adrenal insufficiency. Hypoglycemic attacks did not occur during follow-up while taking steroid therapy and pazopanib. Discussion A single case of primary adrenal insufficiency has been reported in the literature. We here present a case who developed hypoglycemia after pazopanib and was diagnosed with drug-associated secondary adrenal insufficiency. When hypoglycemia develops during pazopanib treatment, we must be aware of adrenal insufficiency.en_US
dc.identifier.doi10.1177/10781552211016081
dc.identifier.endpage2052en_US
dc.identifier.issn1078-1552
dc.identifier.issn1477-092X
dc.identifier.issue8en_US
dc.identifier.pmid33977817en_US
dc.identifier.scopus2-s2.0-85105955099en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage2049en_US
dc.identifier.urihttps://doi.org/10.1177/10781552211016081
dc.identifier.urihttps://hdl.handle.net/20.500.12452/14426
dc.identifier.volume27en_US
dc.identifier.wosWOS:000651175700001en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal Of Oncology Pharmacy Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdrenal Insufficiencyen_US
dc.subjectHypoglycemiaen_US
dc.subjectMalignant Solitary Fibrous Tumoren_US
dc.subjectPazopaniben_US
dc.subjectSarcomaen_US
dc.titlePazopanib-associated secondary adrenal insufficiency in a patient with malignant solitary fibrous tumoren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu